← Leaderboards
Mary Susan Vaughan Sarrazin
University Of Iowa
$1,840,275
Attributed
$1,840,275
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $346.7K · FY2006–22$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,187,443 · 4
AHRQ$652,832 · 2
VA$0 · 1
By mechanism
R01$1,190,789 · 2
R03$343,354 · 3
K18$306,132 · 1
I21$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Iowa
Same institution · by research overlap
- Peter M Cram$10,602,676
- Ioana Popescu$5,749,423
- Paul A Romitti$26,134,328
- Michael Ryan$4,098,514
- Barry London$19,559,318
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseLaboratoriesCessation Of LifePatient-Focused OutcomesPharmaceutical PreparationsOlder PatientChronicPatient SubsetsData SourcesTest ResultBaseClinical TrialsCharacteristicsMedicarePatternAnticoagulantsEffectivenessCostAdherenceCommunity PracticeElderlyAbsorptionAge RelatedAtrial Fibrillation
Grant awards (13)
Assessment of cardiotoxicity in Immunity Checkpoint Blockers and other cancer therapies$0
I21 · FY2022 · VA · contact PI
Assessment of cardiotoxicity in Immunity Checkpoint Blockers and other cancer therapies$0
I21 · FY2020 · VA · contact PI
Dosing of Direct Oral Anticoagulants for stroke prevention in Atrial Fibrillation: Patterns, Consequences, and Guidance$281,363
R01 · FY2019 · AG · contact PI
Dosing of Direct Oral Anticoagulants for stroke prevention in Atrial Fibrillation: Patterns, Consequences, and Guidance$281,363
R01 · FY2018 · AG · contact PI
Dosing of Direct Oral Anticoagulants for stroke prevention in Atrial Fibrillation: Patterns, Consequences, and Guidance$281,363
R01 · FY2017 · AG · contact PI
Stroke Prevention for Atrial Fibrillation with Multiple Chronic Conditions$346,700
R01 · FY2014 · HS · contact PI
Comparative effectiveness of dabigatran and warfarin for stroke prevention in atr$145,405
K18 · FY2013 · HS · contact PI
Comparative effectiveness of dabigatran and warfarin for stroke prevention in atr$160,727
K18 · FY2012 · HS · contact PI
The significance of racial segregation for CV disease$64,450
R03 · FY2007 · AG · contact PI
The significance of racial segregation for CV disease$66,375
R03 · FY2006 · AG · contact PI
Impact of Certificate of Need on the Use of Revascularization for AMI$66,375
R03 · FY2006 · AG · contact PI
GENDER DIFFERENCES IN HEALTH SERVICES UTILIZATION$73,500
R03 · FY2001 · DA
GENDER DIFFERENCES IN HEALTH SERVICES UTILIZATION$72,654
R03 · FY2000 · DA